Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
Jacqueline Claudia Barrientos
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
John Leonard
Consultant or Advisory Role - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Kanti Roop Rai
Research Funding - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences
Marshall T. Schreeder
Research Funding - Gilead Sciences
Nina D. Wagner-Johnston
No relevant relationships to disclose
Jeff Porter Sharman
Research Funding - Gilead Sciences
Thomas E. Boyd
Research Funding - Gilead Sciences
Nathan Hale Fowler
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Daniel Li
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences